Investors
Amplyx is a privately held company advancing the clinical development of fosmanogepix and MAU868 for treatment of life-threatening diseases. Our largest investors are:
Latest News
Milestones Along Our Journey
If you’re a member of the media
and would like to reach Amplyx, please contact:
Heidi Chokeir, Ph.D.
Canale Communications
(619) 849-5377 | heidi@canalecomm.com